Advances in the treatment of CMV.
Cheng
B
B
D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000188:drug therapy*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000077404:Cidofovir; D017321:Clinical Trials, Phase I as Topic; D017326:Clinical Trials, Phase III as Topic; D017726:Cytomegalovirus Retinitis / Q000150:complications / Q000188:drug therapy*; D003596:Cytosine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004343:Drug Implants; D004359:Drug Therapy, Combination; D005123:Eye; D017245:Foscarnet / Q000008:administration & dosage / Q000627:therapeutic use; D015774:Ganciclovir / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000627:therapeutic use; D011788:Quality of Life
D000998:Antiviral Agents; D004343:Drug Implants; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D017245:Foscarnet; D003596:Cytosine; D000077404:Cidofovir; D015774:Ganciclovir